Skip to content
CancerIndex

Loading the knowledge graph…

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) — knowledge graph · CancerIndex